217 related articles for article (PubMed ID: 16077977)
41. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
42. [The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients].
Iba T; Kidokoro A; Fukunaga M; Sugiyama K; Aihara N; Suda M
Gan To Kagaku Ryoho; 2001 Jul; 28(7):973-7. PubMed ID: 11478147
[TBL] [Abstract][Full Text] [Related]
43. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine.
Shimma N; Umeda I; Arasaki M; Murasaki C; Masubuchi K; Kohchi Y; Miwa M; Ura M; Sawada N; Tahara H; Kuruma I; Horii I; Ishitsuka H
Bioorg Med Chem; 2000 Jul; 8(7):1697-706. PubMed ID: 10976516
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Murakami S; Yamamoto Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1147-9. PubMed ID: 17637560
[TBL] [Abstract][Full Text] [Related]
45. [Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
Fujita F; Fujita M; Taguchi T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1635-43. PubMed ID: 6236751
[TBL] [Abstract][Full Text] [Related]
46. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
47. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Ishikawa T; Tanaka Y; Ishitsuka H; Ohkawa T
Jpn J Cancer Res; 1989 Jun; 80(6):583-91. PubMed ID: 2527217
[TBL] [Abstract][Full Text] [Related]
48. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
49. Capecitabine: preclinical pharmacology studies.
Ishitsuka H
Invest New Drugs; 2000 Nov; 18(4):343-54. PubMed ID: 11081570
[TBL] [Abstract][Full Text] [Related]
50. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
[TBL] [Abstract][Full Text] [Related]
51. Capecitabine (Xeloda): from the laboratory to the patient's home.
Pentheroudakis G; Twelves C
Clin Colorectal Cancer; 2002 May; 2(1):16-23. PubMed ID: 12453332
[TBL] [Abstract][Full Text] [Related]
52. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
Oncology; 2007; 73(3-4):228-37. PubMed ID: 18424887
[TBL] [Abstract][Full Text] [Related]
53. Effects of orally administered 5-fluorouracil and its derivative 5'-deoxy-5-fluorouridine on 7,12-dimethylbenz[a]anthracene-induced breast carcinomas in rats.
Sawada Y; Ohno T; Shimoyama T; Uematsu K; Odagiri H
J Int Med Res; 1991; 19(3):249-70. PubMed ID: 1834492
[TBL] [Abstract][Full Text] [Related]
54. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Dhananjeyan MR; Liu J; Bykowski C; Trendel JA; Sarver JG; Ando H; Erhardt PW
J Chromatogr A; 2007 Jan; 1138(1-2):101-8. PubMed ID: 17070825
[TBL] [Abstract][Full Text] [Related]
55. Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
Zhu Y; Xu L; Fan Y; Li C; Zhang Y; Zheng H; Hou K; Qu X; Liu Y
Biomed Res Int; 2013; 2013():132793. PubMed ID: 24027750
[TBL] [Abstract][Full Text] [Related]
56. The rational development of capecitabine from the laboratory to the clinic.
Pentheroudakis G; Twelves C
Anticancer Res; 2002; 22(6B):3589-96. PubMed ID: 12552961
[TBL] [Abstract][Full Text] [Related]
57. [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
Toi M; Taniguchi T; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1995 May; 22(6):799-804. PubMed ID: 7755388
[TBL] [Abstract][Full Text] [Related]
58. Population pharmacokinetic analysis of the major metabolites of capecitabine.
Gieschke R; Reigner B; Blesch KS; Steimer JL
J Pharmacokinet Pharmacodyn; 2002 Feb; 29(1):25-47. PubMed ID: 12194534
[TBL] [Abstract][Full Text] [Related]
59. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
[TBL] [Abstract][Full Text] [Related]
60. [Measurement of 5'-deoxy-5-fluorouridine (5'-DFUR) by high-performance liquid chromatography and studies on pharmacokinetics of 5'-DFUR and 5-fluorouracil by oral and intravenous administration].
Hara Y; Kono A; Tanaka M
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2261-6. PubMed ID: 6237614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
